C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

The 920th Hospital of The Joint Logistics Support Force of the Chinese People's Liberation Army

Status and phase

Enrolling

Phase 1

Conditions

Lymphoma, B-Cell

CAR-T

Treatments

Biological: C752

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT06210243

PH02001

Details and patient eligibility

About

It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.

Enrollment

24 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Written informed consent in accordance with federal, local, and institutional guidelines, Males and females ≥18 years of age at the time of consent
Documented diagnosis of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Have progression by least one systemic treatment and no available standard of care treatment.
At least one measurable lesion by Lugano 2014
Expected survival ≥ 12 weeks
Have an ECOG performance status of 0 or 1
Adequate organ function
Screening test indicates histopathological CD19 + if the subject received CD19-targeted therapy
Women of childbearing age must have a negative pregnancy test, and agree to take effective contraception during the trial

Exclusion criteria

Treatment with any prior HSCT, gene therapy product, cell therapy product ect.
Central nervous system involvement
HBV/HCV
HIV infection
Concurrent use of systemic steroids or immunosuppression
Uncontrolled active infection
Wash-out period of from the last anti-cancer treatment
Active second malignancy
Have not recovered from the effects of previous therapy
Have psychological or physical conditions that do not permit compliance with the protocol
Pregnant or nursing (lactating) women